Aguiar-Ibáñez R - Search Results

1

Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.

Aguiar-Ibáñez R, Hardern C, van Hees F, Lee D, Patel A, Chhabra N, Baluni G, Amonkar M, Lai Y, Xu R, Massaad R, Fogelman D. Aguiar-Ibáñez R, et al. J Med Econ. 2022 Jan-Dec;25(1):469-480. doi: 10.1080/13696998.2022.2043634. J Med Econ. 2022. PMID: 35184650 Free article.

2

A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?

Bullement A, Meng Y, Cooper M, Lee D, Harding TL, O'Regan C, Aguiar-Ibanez R. Bullement A, et al. J Med Econ. 2019 Mar;22(3):205-214. doi: 10.1080/13696998.2018.1547303. Epub 2018 Nov 30. J Med Econ. 2019. PMID: 30422080 Free article. Review.

3

Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.

Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R. Bensimon AG, et al. J Med Econ. 2019 Oct;22(10):981-993. doi: 10.1080/13696998.2019.1609485. Epub 2019 May 17. J Med Econ. 2019. PMID: 31012765 Free article.

4

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.

Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Scherrer E, Wang J, Aguiar-Ibáñez R. Bensimon AG, et al. Clin Drug Investig. 2020 Jul;40(7):629-643. doi: 10.1007/s40261-020-00922-6. Clin Drug Investig. 2020. PMID: 32418051 Free PMC article.

5

Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina.

Wurcel V, Scherrer E, Aguiar-Ibanez R, Altuna JI, Carabajal F, Jain S, Baluni G. Wurcel V, et al. Among authors: aguiar ibanez r. Oncol Ther. 2021 Jun;9(1):167-185. doi: 10.1007/s40487-021-00142-8. Epub 2021 Feb 23. Oncol Ther. 2021. PMID: 33624271 Free PMC article.

6

Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.

Thurgar E, Gouldson M, Matthijsse S, Amonkar M, Marinello P, Upadhyay N, Nwankwo C, Aguiar-Ibáñez R. Thurgar E, et al. Among authors: aguiar ibanez r. J Med Econ. 2021 Jan-Dec;24(1):675-688. doi: 10.1080/13696998.2021.1917140. J Med Econ. 2021. PMID: 33866938 Free article.

7

Cost-Effectiveness of Pembrolizumab Versus Carboplatin and Paclitaxel in Patients With Unresectable or Metastatic Melanoma After First-Line Treatment in China.

Tang WX, Shao RJ, Wang J, Scherrer E, Ma AX, Aguiar-Ibáñez R. Tang WX, et al. Among authors: aguiar ibanez r. Value Health Reg Issues. 2022 Jan-Feb;27:99-107. doi: 10.1016/j.vhri.2021.04.007. Epub 2021 Dec 16. Value Health Reg Issues. 2022. PMID: 34922053 Free article.

8

How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?

Cooper M, Smith S, Williams T, Aguiar-Ibáñez R. Cooper M, et al. Among authors: aguiar ibanez r. J Med Econ. 2022 Jan-Dec;25(1):260-273. doi: 10.1080/13696998.2022.2030599. J Med Econ. 2022. PMID: 35060433 Free article.

9

Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC.

Jin H, Amonkar M, Aguiar-Ibáñez R, Thosar M, Chase M, Keeping S. Jin H, et al. Among authors: aguiar ibanez r. Future Oncol. 2022 Jun;18(17):2155-2171. doi: 10.2217/fon-2021-1633. Epub 2022 Mar 25. Future Oncol. 2022. PMID: 35332802 Review.

10

Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.

McCarthy G, Young K, Madin-Warburton M, Mantaian T, Brook E, Metcalfe K, Mikelson J, Xu R, Seyla-Hammer C, Aguiar-Ibáñez R, Amonkar M. McCarthy G, et al. Among authors: aguiar ibanez r. J Med Econ. 2024 Jan-Dec;27(1):279-291. doi: 10.1080/13696998.2024.2311507. Epub 2024 Feb 19. J Med Econ. 2024. PMID: 38293714 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters